公开(公告)号：WO9603506A3

公开(公告)日：1996-03-07

申请号：PCT/CA9500434

申请日：1995-07-21

Applicant: CONNAUGHT LAB ,  LOOSMORE SHEENA M ,  YANG YAN PING ,  CHONG PELE ,  OOMEN RAYMOND P ,  KLEIN MICHEL H

Inventor： LOOSMORE SHEENA M ,  YANG YAN-PING ,  CHONG PELE ,  OOMEN RAYMOND P ,  KLEIN MICHEL H

IPC: A61K39/00 ,  C07K14/285 ,  C12N9/52 ,  C12N15/31 ,  A61K39/102 ,  C07K19/00 ,  C12N1/21 ,  C12N15/70 ,  G01N33/569

CPC classification number: C07K14/285 ,  A61K39/00 ,  A61K2039/51 ,  C07K2319/00 ,  C12N9/52

Abstract: The invention concerns isolated and purified analogs of Haemophilus influenza Hin47 protein with decreased protease activity (of less than 10 % of that of the natural protein) but preferably retaining substantially the same immunogenic properties as natural Hin47. Preferred analogs have mutations at Ser197, His91 and/or Asp121 positions and are possibly used as chimeric proteins with other immunogenic molecules. Also disclosed are nucleic acid encoding said analogs, recombinant plasmids and transformed host cells containing said modified genes, immunogenic compositions containing Hin47 analogs or their nucleic acid and their use for prophylactic, vaccine or diagnostic purposes.

公开(公告)号：WO9640929A3

公开(公告)日：1997-03-06

申请号：PCT/CA9600399

申请日：1996-06-07

Applicant: CONNAUGHT LAB ,  LOOSMORE SHEENA M ,  HARKNESS ROBIN E ,  SCHRYVERS ANTHONY B ,  CHONG PELE ,  GRAY OWEN SCOTT ,  YANG YAN PING ,  MURDIN ANDREW D ,  KLEIN MICHEL H

Inventor： LOOSMORE SHEENA M ,  HARKNESS ROBIN E ,  SCHRYVERS ANTHONY B ,  CHONG PELE ,  GRAY-OWEN SCOTT ,  YANG YAN-PING ,  MURDIN ANDREW D ,  KLEIN MICHEL H

IPC: C12N15/09 ,  A61K39/00 ,  A61K39/102 ,  A61K48/00 ,  A61P31/00 ,  A61P31/04 ,  C07K14/285 ,  C12N1/21 ,  C12N5/10 ,  C12N15/31 ,  C12P21/02 ,  C12N15/70 ,  C12N15/86

CPC classification number: C07K14/285 ,  A61K39/00 ,  A61K2039/51 ,  C12N2799/021

Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.

公开(公告)号：WO9315205A3

公开(公告)日：1994-03-03

申请号：PCT/CA9300041

申请日：1993-02-03

Applicant: CONNAUGHT LAB

Inventor： CHONG PELE ,  KANDIL ALI ,  SIA CHARLES ,  KLEIN MICHEL H

IPC: G01N33/53 ,  A61K31/00 ,  A61K39/00 ,  A61K39/102 ,  A61K39/21 ,  A61K39/385 ,  A61K39/39 ,  A61K39/395 ,  A61K47/48 ,  A61P31/00 ,  A61P31/04 ,  A61P37/04 ,  C07H15/04 ,  C07H15/08 ,  C07H15/18 ,  C07H21/04 ,  C07K7/08 ,  C07K14/11 ,  C07K14/16 ,  C07K14/195 ,  C07K14/285 ,  C07K16/00 ,  C12N15/09 ,  C12N15/31 ,  G01N33/569 ,  C07K7/10 ,  C07K15/00 ,  C12N15/63

CPC classification number: C07H15/04 ,  A61K39/00 ,  A61K47/60 ,  A61K47/646 ,  C07H15/08 ,  C07H15/18 ,  C07K14/285 ,  Y02P20/55 ,  Y10S435/851

Abstract: PCT No. PCT/CA93/00041 Sec. 371 Date Oct. 3, 1994 Sec. 102(e) Date Oct. 3, 1994 PCT Filed Feb. 3, 1993 PCT Pub. No. WO93/15205 PCT Pub. Date Aug. 5, 1993The present invention provides immunogenic synthetic peptides which are useful alone or in PRP-conjugates in vaccines against Hemophilus influenza infection. Modifications are possible within the scope of the invention.

公开(公告)号：WO9314206A3

公开(公告)日：1993-10-28

申请号：PCT/CA9300014

申请日：1993-01-20

Applicant: CONNAUGHT LAB

Inventor： CHONG PELE ,  GILLAM SHIRLEY ,  OU DAWEI ,  TINGLE AUBREY

IPC: G01N33/50 ,  A61K38/00 ,  A61K39/00 ,  A61K39/20 ,  A61P31/12 ,  C07K14/19 ,  C07K16/00 ,  C07K16/10 ,  C12N15/09 ,  C12N15/40 ,  C12N15/62 ,  C12N15/85 ,  C12P21/02 ,  C12P21/08 ,  G01N33/53 ,  C07K15/28

CPC classification number: C07K14/005 ,  A61K38/00 ,  A61K39/00 ,  C12N2770/36222 ,  Y10S530/826

Abstract: Synthetic peptides have an amino acids sequence corresponding to at least one antigenic determinant of at least one protein, usually a structural protein, particularly the E1, E2 or C proteins, of rubella virus (RV), are used as is, in hybrid or chimeric tandem T-B form, in lipidated form, linked to a carrier molecule and/or polymerized to form molecular aggregates, in vaccines against rubella. Analogs of peptides which are human T-cell determinants are used to treat rubella-associated autoimmune disorders.